Ignite Creation Date:
2025-12-24 @ 11:44 PM
Ignite Modification Date:
2025-12-25 @ 9:37 PM
Study NCT ID:
NCT01250951
Status:
COMPLETED
Last Update Posted:
2016-12-12
First Post:
2010-11-11
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-12
Start Date Type:
None
Primary Completion Date:
2011-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2011-09
Completion Date Type:
ACTUAL
First Submit Date:
2010-11-11
First Submit QC Date:
None
Study First Post Date:
2010-12-01
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2016-12-08
Last Update Post Date:
2016-12-12
Last Update Post Date Type:
ESTIMATED